Ribo's RBD1016 Receives Orphan Drug Designation to Fight Delta Hepatitis Virus Infection Ribo Life Science's RBD1016 has gained orphan drug status from the EMA for treating Delta hepatitis, improving treatment options for patients.

Ribo's RBD1016 Receives Orphan Drug Designation to Fight Delta Hepatitis Virus Infection #Sweden #Gothenburg #Ribo_Life_Science #RBD1016 #EMA_Orphan_Drug

Ribo Achieves Significant Milestone with EMA's Orphan Drug Designation for RBD1016 to Treat Hepatitis Delta Virus Suzhou Ribo Life Science and Ribocure Pharmaceuticals have secured the EMA's Orphan Drug Designation for RBD1016, a promising siRNA therapy against Hepatitis Delta Virus.

Ribo Achieves Significant Milestone with EMA's Orphan Drug Designation for RBD1016 to Treat Hepatitis Delta Virus #China #Suzhou #Ribo_Life_Science #RBD1016 #Ribocure_Pharmaceuticals

Ribo Receives EMA Orphan Drug Status for RBD1016 Against Hepatitis D Infection Ribo Life Science's siRNA therapy RBD1016 has been granted Orphan Drug Designation by the EMA for treating Hepatitis D, enhancing its development potential.

Ribo Receives EMA Orphan Drug Status for RBD1016 Against Hepatitis D Infection #China #Suzhou #Ribo_Life_Science #RBD1016 #Hepatitis_D

Ribo's RBD1016 Receives EMA Orphan Drug Designation for HDV Treatment Following the recent EMA Orphan Drug Designation, Ribo advances its siRNA therapeutic RBD1016 for treating Hepatitis Delta Virus (HDV) infection.

Ribo's RBD1016 Receives EMA Orphan Drug Designation for HDV Treatment #None #Ribo_Life_Science #RBD1016 #Hepatitis_Virus